Abstract:Abstract Long-lived species Homo sapiens have evolved robust protection mechanisms against cancer by repressing telomerase and maintaining short telomeres, thereby delaying the onset of the majority of cancer types until post-reproductive age. Indeed, telomerase is silent in most differentiated human cells, predominantly due to the transcriptional repression of its catalytic component telomerase reverse transcriptase (TERT) gene. The lack of telomerase/TERT expression leads to progressive telomere erosion in dividing human cells, whereas critically shortened telomere length induces a permanent growth arrest stage named replicative senescence. TERT/telomerase activation has been experimentally shown to be essential to cellular immortalization and malignant transformation by stabilizing telomere length and erasing the senescence barrier. Consistently, TERT expression/telomerase activity is detectable in up to 90% of human primary cancers. Compelling evidence has also accumulated that TERT contributes to cancer development and progression via multiple activities beyond its canonical telomere-lengthening function. Given these key roles of telomerase and TERT in oncogenesis, great efforts have been made to decipher mechanisms underlying telomerase activation and TERT induction. In the last two decades since the TERT gene and promoter were cloned, the derepression of the TERT gene has been shown to be achieved typically at a transcriptional level through dysregulation of oncogenic factors or signaling, post-transcriptional/translational regulation and genomic amplification. However, advances in high-throughput next-generation sequencing technologies have prompted a revolution in cancer genomics, which leads to the recent discovery that genomic alterations take center stage in activating the TERT gene. In this review article, we summarize critical mechanisms activating TERT transcription, with special emphases on the contribution of TERT promoter mutations and structural alterations at the TERT locus, and briefly discuss the underlying implications of these genomic events-driven TERT hyperactivity in cancer initiation/progression and potential clinical applications as well.

The regulations of telomerase reverse transcriptase (TERT) in cancer

Feedback regulation of telomerase reverse transcriptase: new insight into the evolving field of telomerase in cancer

Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players

Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications

Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer

Argininosuccinate Lyase Drives Activation of Mutant TERT Promoter in Glioblastomas

Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene

Regulation Of Telomerase Activity By Apparently Opposing Elements

Regulation of human telomerase in homeostasis and disease

Transcriptional regulation mechanism and targeted cancer therapy of human telomerase reverse transcriptase promoter

Regulation of telomerase towards tumor therapy

MicroRNA Regulation of Telomerase Reverse Transcriptase (TERT): Micro Machines Pull Strings of Papier-Mâché Puppets

Transcriptional Regulation of Telomerase Activity

Association of Telomerase Reverse Transcriptase Promoter Mutations with Clinicopathological Features and Prognosis of Thyroid Cancer: a Meta-Analysis.

Discriminating Association of a Common Telomerase Reverse Transcriptase Promoter Polymorphism with Telomere Parameters in Non-Small Cell Lung Cancer with or Without Epidermal Growth Factor Receptor Mutation.

Telomerase mutations and carcinogenesis

Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression.

Multiple Actions of Telomerase Reverse Transcriptase in Cell Death Regulation

Inhibition of telomerase by targeting MAP kinase signaling.

The TERT Promoter Mutation Incidence is Modified by Germline TERT Rs2736098 and Rs2736100 Polymorphisms in Hepatocellular Carcinoma

Hormones and growth factors regulate telomerase activity in ageing and cancer